{"data":[{"vaccine_id":4322,"vaccine_name":"2008–2009 trivalent influenza vaccine","pathogen_id":50,"type":"Inactivated or \"killed\" vaccine","description":null,"status":"Licensed","vo_id":"VO_0004809","manufacturer":null,"is_combination_vaccine":"1"},{"vaccine_id":4324,"vaccine_name":"2011–2012  trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008).","pathogen_id":50,"type":"Inactivated or \"killed\" vaccine","description":null,"status":"Licensed","vo_id":"VO_0004810","manufacturer":null,"is_combination_vaccine":"1"},{"vaccine_id":438,"vaccine_name":"5CVMB","pathogen_id":46,"type":"Subunit vaccine","description":null,"status":"Licensed","vo_id":"VO_0011348","manufacturer":null,"is_combination_vaccine":"No"},{"vaccine_id":5713,"vaccine_name":"aaa","pathogen_id":99,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":96,"vaccine_name":"ACAM2000","pathogen_id":18,"type":"Replication competent virus","description":"The benefits of cloning appeared to outweigh the recognized risk that a clonal virus population may differ biologically from the ‘genetic swarm’ represented by the animal-skin vaccine. Because it would not be possible to conduct field tests for efficacy, the new vaccine would need to match the licensed vaccine (Dryvax®) as closely as possible in preclinical tests for safety, immunogenicity, and protective activity and in clinical trials for safety and immunogenicity [Ref144: Monath et al., 2004].\r\nClinical trials have been conducted using the NYCBH-derived ACAM2000 vaccinia virus-based vaccine. On the basis of animal studies, ACAM2000 is believed to be less neurovirulent than Dryvax. ACAM2000 was similar to Dryvax in its ability to induce immune responses and in reactogenicity in phase I trials. During phase II and phase III clinical trials, cases of myopericarditis were associated with both ACAM2000 and Dryvax in vaccinia-naive volunteers [Ref135:Parrino et al., 2006].","status":"Licensed","vo_id":"VO_0000003","manufacturer":"Acambis, Inc","is_combination_vaccine":"No"},{"vaccine_id":6149,"vaccine_name":"ACAM3000","pathogen_id":18,"type":"Replication competent virus","description":null,"status":"Licensed","vo_id":null,"manufacturer":"ACAMBIS, Inc","is_combination_vaccine":"0"},{"vaccine_id":554,"vaccine_name":"Actacel","pathogen_id":62,"type":"Subunit vaccine","description":"Products: Proteins + Conjugate.","status":"Licensed","vo_id":"VO_0010705","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":555,"vaccine_name":"Actacel","pathogen_id":41,"type":"Subunit vaccine","description":"Products: Proteins + Conjugate.","status":"Licensed","vo_id":"VO_0010705","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":556,"vaccine_name":"Actacel","pathogen_id":85,"type":"Subunit vaccine","description":"Products: Proteins + Conjugate.","status":"Licensed","vo_id":"VO_0010705","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":557,"vaccine_name":"Actacel","pathogen_id":31,"type":"Subunit vaccine","description":"Products: Proteins + Conjugate.","status":"Licensed","vo_id":"VO_0010705","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":761,"vaccine_name":"Actacel","pathogen_id":109,"type":"Subunit vaccine","description":"Products: Proteins + Conjugate.","status":"Licensed","vo_id":"VO_0010705","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":157,"vaccine_name":"ActHIB","pathogen_id":31,"type":"Conjugate vaccine","description":" ActHIB vaccine was among the first conjugated Hib vaccines developed at the National Institutes of Health (NIH). It is now manufactured by Sanofi Pasteur SA in Lyon, France. The conjugation process changes the polysaccharide from a “T-cell–independent antigen” to a “T-cell–dependent antigen”, which greatly improves immunogenicity, particularly in young children. In addition, repeated doses elicit a substantial booster response in children who have been previously vaccinated [Ref257:ActHIB 2005]. ","status":"Licensed","vo_id":"VO_0000004","manufacturer":"Sanofi Pasteur, SA","is_combination_vaccine":"No"},{"vaccine_id":6008,"vaccine_name":"Ad26/protein preF RSV Vaccine Coadministered With an Influenza Vaccine","pathogen_id":212,"type":"Other","description":"[Ref5639:Sadoff et al., 2021]  The vaccine Ad26.RSV.preF is the next-generation vaccine expressing the stabilized FA2. The vaccine is a replication-incompetent Ad26 vector containing a DNA transgene, encoding a F protein derived from the RSV A2 strain that is stabilized in its pre-F conformation","status":"Licensed","vo_id":null,"manufacturer":"Janssen (Leiden, the Netherlands)","is_combination_vaccine":"Yes"},{"vaccine_id":5760,"vaccine_name":"Ad41.MERS-S protein","pathogen_id":319,"type":"Recombinant vector vaccine","description":"Adenovirus type 41 used as vector for MERS-CoV S protein [Ref5396:Guo et al., 2015]","status":"Licensed","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":4278,"vaccine_name":"Ad5-Ag85A (Tuberculosis)","pathogen_id":219,"type":"Recombinant vector vaccine","description":null,"status":"Licensed","vo_id":null,"manufacturer":null,"is_combination_vaccine":"0"},{"vaccine_id":371,"vaccine_name":"Adacel","pathogen_id":62,"type":"Toxoid vaccine","description":"It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.","status":"Licensed","vo_id":"VO_0000005","manufacturer":"Sanofi Pasteur, Ltd (USA: License #1726)","is_combination_vaccine":"No"},{"vaccine_id":383,"vaccine_name":"Adacel","pathogen_id":41,"type":"Toxoid vaccine","description":"It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.[Ref806:FDA: Adacel]","status":"Licensed","vo_id":"VO_0000005","manufacturer":"Sanofi Pasteur, Ltd (USA: License #1726)","is_combination_vaccine":"No"},{"vaccine_id":558,"vaccine_name":"Adacel","pathogen_id":85,"type":"Subunit vaccine","description":"Products: Proteins.","status":"Licensed","vo_id":"VO_0000005","manufacturer":"Sanofi Pasteur Ltd","is_combination_vaccine":"No"},{"vaccine_id":774,"vaccine_name":"Adacel","pathogen_id":109,"type":"Toxoid vaccine","description":"It is a sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components adsorbed onto aluminum phosphate, for intramuscular administration.","status":"Licensed","vo_id":"VO_0000005","manufacturer":"Sanofi Pasteur, Ltd (USA: License #1726)","is_combination_vaccine":"No"},{"vaccine_id":5549,"vaccine_name":"Adacel-Polio","pathogen_id":55,"type":"Toxoid vaccine + Subunit vaccine + Inactivated or \"killed\" vaccine","description":"ADACEL®-POLIO is a sterile, uniform, cloudy, white suspension of tetanus and diphtheria toxoids and acellular pertussis vaccine adsorbed separately on aluminum phosphate and combined with inactivated poliomyelitis vaccine (vero cell origin) types 1, 2 and 3, and suspended in water for injection. Acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN and FIM). [Ref4067:Product Monograph: Adacel-Polio]","status":"Licensed","vo_id":"VO_0003085","manufacturer":"Sanofi Pasteur SA","is_combination_vaccine":"Yes"},{"vaccine_id":5571,"vaccine_name":"Adacel-Polio","pathogen_id":62,"type":"Toxoid vaccine + Subunit vaccine + Inactivated or \"killed\" vaccine","description":"ADACEL®-POLIO is a sterile, uniform, cloudy, white suspension of tetanus and diphtheria toxoids and acellular pertussis vaccine adsorbed separately on aluminum phosphate and combined with inactivated poliomyelitis vaccine (vero cell origin) types 1, 2 and 3, and suspended in water for injection. Acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN and FIM). [Ref4068:Product Monograph: Adacel-Polio]","status":"Licensed","vo_id":"VO_0003085","manufacturer":"Sanofi Pasteur SA","is_combination_vaccine":"Yes"},{"vaccine_id":5579,"vaccine_name":"Adacel-Polio","pathogen_id":109,"type":"Toxoid vaccine + Subunit vaccine + Inactivated or \"killed\" vaccine","description":"ADACEL®-POLIO is a sterile, uniform, cloudy, white suspension of tetanus and diphtheria toxoids and acellular pertussis vaccine adsorbed separately on aluminum phosphate and combined with inactivated poliomyelitis vaccine (vero cell origin) types 1, 2 and 3, and suspended in water for injection. Acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN and FIM). [Ref4095:Product Monograph: Adacel-Polio]","status":"Licensed","vo_id":"VO_0003085","manufacturer":"Sanofi Pasteur SA","is_combination_vaccine":"1"},{"vaccine_id":5583,"vaccine_name":"Adacel-Polio","pathogen_id":41,"type":"Toxoid vaccine + Subunit vaccine + Inactivated or \"killed\" vaccine","description":"ADACEL®-POLIO is a sterile, uniform, cloudy, white suspension of tetanus and diphtheria toxoids and acellular pertussis vaccine adsorbed separately on aluminum phosphate and combined with inactivated poliomyelitis vaccine (vero cell origin) types 1, 2 and 3, and suspended in water for injection. Acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN and FIM). [Ref4106:Product Monograph: Adacel-Polio]","status":"Licensed","vo_id":"VO_0003085","manufacturer":"Sanofi Pasteur SA","is_combination_vaccine":"Yes"},{"vaccine_id":3116,"vaccine_name":"Adenovirus Type 4 and Type 7 Vaccine, Live, Oral","pathogen_id":216,"type":"Live vaccine","description":"Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7, virus strains have not been attenuated. The vaccine is composed of two tablets (one of Adenovirus type 4 and one Adenovirus type 7) designed to pass intact through the stomach and release the live virus in the intestine [Ref2070:FDA: Adenovirus Vaccine].","status":"Licensed","vo_id":"VO_0000096","manufacturer":"Barr Labs, Inc.","is_combination_vaccine":"No"},{"vaccine_id":3963,"vaccine_name":"AE-Poxine","pathogen_id":148,"type":"Live, attenuated vaccine","description":null,"status":"Licensed","vo_id":"VO_0004603","manufacturer":"Zoetis","is_combination_vaccine":"0"}],"meta":{"page":1,"per_page":25,"count":25,"total":2541}}